Infinityseek Launches Innovative Omega-3 Solution at BioST 2025 SG

The 5th World Biological Science and Technology Conference, known as BioST 2025 SG, commenced in Singapore on December 17, 2025. During this prominent event, the pioneering longevity brand infinityseek unveiled its innovative anti-aging solution, garnering considerable interest from researchers and industry experts in the global biotechnology sector. The focus of infinityseek’s presentation centered on advancements in vascular aging research and its latest microalgae-based Omega-3 product.

According to the Global Burden of Cardiovascular Diseases and Risk Factors Report, cardiovascular diseases (CVDs) accounted for the leading cause of death worldwide, with approximately 437 million cases of associated disability recorded in 2023. Current treatments primarily address the later stages of CVDs, leaving a gap in interventions that target the fundamental pathological processes behind systemic vascular aging. Infinityseek aims to bridge this gap through its research on natural bio-resources, focusing on both inflammation resolution and lipid metabolism.

The brand’s groundbreaking discovery involves the rare microalgae Nannochloropsis. In its presentation, infinityseek’s scientific advisor emphasized the advantages of this microalgae-derived formulation compared to conventional Omega-3 sources such as fish or krill. Nannochloropsis, which has existed for approximately 3.5 billion years and sits at the base of the marine food chain, is noted for its exceptional purity and ability to avoid contaminant accumulation. This ensures the safety and cleanliness of its components right from the source.

Infinityseek’s formulation demonstrates significantly enhanced bioavailability, deriving from its natural polar lipid structure, which aligns well with human physiology. Experimental data indicates that its bioavailability is 2.2 times higher than that of 97% EPA fish oil, with a notable 56% increase in key tissue accumulation. This product operates through clear mechanisms, addressing two critical pathways of vascular aging.

The formulation’s abundant Ultra SPMs—third-generation specialized pro-resolving mediators—exhibit powerful anti-inflammatory properties within eight weeks, effectively reducing the four major senescence-associated secretory phenotypes (SASPs). Additionally, its unique formulation of 100% Uni-EPA, free of DHA, precisely regulates lipid metabolism within four weeks, achieving targeted lipid-lowering effects. By simultaneously modulating inflammation resolution and lipid metabolism, infinityseek’s solution is designed to slow vascular aging and promote long-term systemic health outcomes.

Infinityseek’s breakthrough reflects its commitment to rigorous scientific standards and a global evidence-based framework. The company has established the Longevity Lab and collaborates with international institutions, including Lipidomix GmbH in Germany, to create a comprehensive scientific system that ranges from fundamental research to product validation. Its products have already received multiple authoritative certifications in China, the United States, and Germany.

Jains Pang, an R&D expert at infinityseek, stated, “infinityseek’s core philosophy lies in a profound respect for science and steadfast dedication to long-term, challenging scientific exploration and public education. Our goal is to enhance fundamental understanding of health and provide truly systemic and effective solutions.”

The formal publication of infinityseek’s research on top-tier international academic platforms not only showcases its expertise in vascular aging interventions but also marks a significant shift in the healthcare industry. This transition emphasizes a deeper understanding of mechanisms and the integration of global scientific knowledge. Infinityseek’s advancements pave the way for addressing age-related health challenges on an international scale, offering hope for improved health outcomes in the fight against cardiovascular diseases.